Fractyl Health (GUTS) Q3 2024 earnings summary

Executive summary

• Achieved key milestones in Q3 2024, including rapid enrollment in pivotal REMAIN-1 and REVITALIZE-1 studies for weight maintenance and type 2 diabetes, respectively.

• Presented compelling real-world and pooled clinical data for Revita, showing durable weight loss and metabolic benefits up to one year post-procedure.

• Advanced Rejuva gene therapy platform, with new preclinical data demonstrating durable efficacy and nomination of a dual agonist candidate for obesity.

• Completed IPO in February 2024, raising net proceeds of $98.9M, with all preferred stock and 2022 convertible notes converted to common stock.

• Revita is approved in Europe with a limited commercial launch in Germany; no US product approvals yet.

Financial highlights

• Q3 2024 revenue was $14,000, generated from the pilot commercial launch in Germany and patient enrollment in the German registry, down 61% year-over-year.

• Research and development expenses rose to $19.0M in Q3 2024, up 103% year-over-year, driven by clinical progress and increased personnel costs.

• SG&A expenses increased to $4.8M in Q3 2024, up 7% year-over-year.

• Net loss for Q3 2024 was $23.2M, compared to $15.7M in Q3 2023.

• Cash and cash equivalents totaled $84.7M as of September 30, 2024, expected to fund operations into Q4 2025.

Outlook and guidance

• REMAIN-1 midpoint analysis expected in Q2 2025, with full data to follow; REVEAL-1 open-label data to be shared at year-end and updated through 2025.

• REVITALIZE-1 topline data for type 2 diabetes anticipated mid-2025.

• Rejuva-001 CTA-enabling studies to complete by year-end, with first-in-human study planned for H1 2025 pending regulatory approval.

• Controlled commercial expansion in Germany planned for 2025, with additional registry data to be disclosed in Q1 2025 and global launch preparations underway.

• Expect continued significant operating losses and need for substantial additional funding to support ongoing R&D and commercialization efforts.